

Figure S1. Illustration of the experimental schedule for the induction of atopic dermatitis-like skin lesions and intravenous administration of Tomaralimab.




Figure S2. HaCaT cells were treated with varying concentrations of DNCB (0, 5, 10, 25 and 50 nM) for 24 h and cell viability was determined. The cell viability for the control group received with the vehicle (DMSO) was set to 100%. Results are expressed as the mean  $\pm$  SD (n=3). DNCB, 2,4-dinitrochlorobenzene.

